On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act took effect. MediPharm Labs has already supplied product for over 10 active clinical trials, including a U.S. National Institutes of Health funded study, and has completed multiple API and clinical trial material shipments to the United States.
Click here for the full story.
1 | Curaleaf completes buyout of remaining stake in Germany’s Four 20 Pharma
2 | Glow Lifetech expands distribution with two of Canada’s largest cannabis retailers
3 | HYTN exports GMP-manufactured vape cartridges
Top Cannabis Stocks Apr. 25 to Apr. 30, 2026
1. T.CURA | 12,254 views | Curaleaf Holdings Inc.
2. T.TLRY | 5,89 views | Tilray Brands Inc.
3. T.LABS | 4,540 views | Medipharm Labs Corp.
4. T.ACB| 1,198 views | Aurora Cannabis Inc.
5. C.TGIF | 1,746 views | 1933 Industries Inc.
6. T.OGI | 687 views | Organigram Global Inc.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.